TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00782405
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XR, 150-300mg
Study: NCT00077025
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZD1839 (gefitinib, IRESSA) 250 mg/DAY PO + 1 mg Anastrozole (ZD1033, Arimidex)
Study: NCT00077025
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg Anastrozole (ZD1033, Arimidex) + PLACEBO 1 TABLET/DAY PO
Study: NCT03507166
Drug: RC48-ADC
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg/kg IV every 2 weeks
Study: NCT02828111
Drug: Patidegib
Normalized name: Patidegib
DrugBank: Patidegib (DB12655)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00782405
Drug: mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-45 mg
Study: NCT01168817
Drug: BAY60-4552 plus Vardenafil
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with 3 tablets once daily for 4 weeks (Vardenafil 10 mg plus BAY60-4552 1.0 mg)
Study: NCT01168817
Drug: Vardenafil
Normalized name: Vardenafil
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with 3 tablets once daily for 4 weeks (Vardenafil 20 mg)
Study: NCT04117932
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab (90 mg subcutaneously at weeks 0, 4, 16), in association with topical superpotent corticosteroid (10-30 g per day during the first 4 weeks, then every other day during 4 weeks).
Study: NCT01869751
Drug: Prucalopride
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment with prucalopride for slow-transit constipation
Study: NCT00123916
Drug: Benznidazole
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily po Benznidazole or placebo (weight based) during 40 - 80 days (depending on body weight)
Study: NCT00781599
Drug: Chantix
Normalized name: Chantix
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3
Study: NCT03220191
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: palbociclib tablet formulation
Study: NCT03220191
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rabeprazole as PPI
Study: NCT03912857
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental: test group Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.~Apatinib :250 mg or 375 mg, qd
Study: NCT05369650
Drug: Lidocaine Hydrochloride, Injectable
Normalized name: Lidocaine Hydrochloride, Injectable
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The lidocaine group 1, 1.5 and 2 groups were injected with 1% lidocaine 1.5mg/kg (ideal body weight, 10min infusion) after anesthesia induction, respectively, and then continued to infuse 1% lidocaine. 1mg/kg.h, 1.5mg/kg.h, 2mg/kg.h (ideal body weight) until the end of the operation, and a patient-controlled intravenous analgesia (PCIA) pump containing lidocaine (PCIA) 0.3-1.5mg/kg after surgery. h to 72h after surgery.
Study: NCT00235976
Drug: Gantacurium Chloride for Injection (AV430A)
Normalized name: potassium chloride Powder for Oral Solution
DrugBank: Gantacurium (DB05710)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00089440
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03043664
Drug: Lanreotide
Normalized name: Lanreotide
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Somatuline depot (lanreotide) 90 mg SQ every 3 weeks
Study: NCT03043664
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Keytruda (pembrolizumab) 200 mg IV every 3 weeks
Study: NCT03033303
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days -4 to 0: GM-CSF 250 mcg/m2/day, subcutaneously. Days 1 to 5: GM-CSF 500 mcg/m2/day, subcutaneously.
Study: NCT03033303
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin is administered at 160 mg/m2/d, divided into two doses, x14 days.
Study: NCT02412930
Drug: Group Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in group T were given intravenously a loading dose of tramadol of 1 mgkg-1, 45 minutes before the end of surgery. After,patients in both groups were performed patient controlled analgesia (PCA). The PCA (CADD Legacy PCA pump, Smiths Medical MD, Inc., St. Paul, MN) was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.
Study: NCT02412930
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01985594
Drug: utrogestan
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Tablet Utrogestan 400 mg daily for 2 days
Study: NCT01985594
Drug: Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet Nifedipine 20 mg stat then 20 mg after 30 minutes if contraction persist and another 20mg after 30 minutes if contraction still persist followed by 10 mg three times daily for 2 days
Study: NCT02864082
Drug: PAT-001, 0.1%
DrugBank: AT-001 (DB15121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.
Study: NCT02864082
Drug: PAT-001, 0.2%
DrugBank: AT-001 (DB15121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.
Study: NCT02864082
Drug: Vehicle for PAT-001 0.1%
DrugBank: AT-001 (DB15121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.1%.
Study: NCT02864082
Drug: Vehicle for PAT-001 0.2%
DrugBank: AT-001 (DB15121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.2%.
Study: NCT03713593
Drug: lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally once a day
Study: NCT03447769
Drug: Canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg of canakinumab administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Canakinumab solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
Study: NCT00551538
Drug: Lispro mix 75/25
Normalized name: Insulin Lispro Protamine-Insulin Lispro Mix 75/25 KwikPen
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lispro mix 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
Study: NCT01127178
Drug: E7016 + TMZ
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-Dose PK Period (single oral dose of E7016 on Day -7) in the Dose-Escalation Component; Multiple-Dose Treatment Cycles (7 days of oral E7016 + 5 days of oral TMZ) added in Cycle 1 of the Dose-Escalation Component and in Cycles 1 through 6 of the Expansion Component.
Study: NCT00153764
Drug: Cooper Complete One-A-Day Vitamin Supplement
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02758431
Drug: Acyline
Normalized name: Acyline
DrugBank: Acyline (DB11906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyline 300ug/kg injection will be administered on Day 0 and on day 14
Study: NCT00551538
Drug: Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SC injection, once-daily, given in conjunction with oral antidiabetic medications.
Study: NCT02758431
Drug: Arimidex
Normalized name: Arimidex
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arimidex Oral Tablet 1mg taken orally daily for 28 days
Study: NCT04139317
Drug: Capmatinib
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: INC280 tablets were administered orally at 400 mg on a continuous twice daily (BID) dosing schedule, from Day 1 until Day 21 of each 21-day cycle.
Study: NCT04387084
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04387084
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02785406
Drug: suvorexant
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.
Study: NCT02785406
Drug: Placebo (for suvorexant)
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive placebo capsules once daily at 10 PM.
Study: NCT00991250
Drug: Temodal® or Dacarbazine Medac®
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (5-\[3,3-Dimethyl-1-triazenyl\]imidazole-4-carboxamide) is a widely used systemic treatment against advanced malignant melanoma. Dacarbazine is a cytostatic agent, which inhibits tumour growth by interfering with DNA-synthesises. The DNA-synthesis is inhibited by alkylation of the DNA molecule; however, it is unclear whether dacarbazine has other cytostatic impacts on cell mechanisms. Dacarbazine is inactive until liver passage, the liver converts dacarbazine to its reactive metabolites MTIC and HMMTIC, which alkylate DNA. Dacarbazine is light sensitive and needs to be administered intravenously.~A newer analogue to dacarbazine, temozolomide (Temodal®), has been developed for oral administration. Temodal® is administered in capsules and is rapidly absorbed reaching peak concentrations after 20 minutes. Temodal® is converted to MTIC at physiological pH, the same reactive molecule as dacarbazine is metabolized to in the liver.
Study: NCT01155947
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
Study: NCT00511004
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparing 400 mg to 800 mg dose
Study: NCT00511004
Drug: Diethylcarbamazine
Normalized name: Diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Providing diethylcarbamazine more frequently in combination with albendazole
Study: NCT04642638
Drug: INO-4800
Normalized name: INO-4800
DrugBank: INO-4800 (DB15693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INO-4800 was administered ID on Day 0 and Day 28.
Study: NCT00990652
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Before surgery, an injection of bortezomib is given on days 1, 4, and 8. After surgery, bortezomib is given on days 7 and 21 of each cycle (1 cycle = 28 days).
Study: NCT00990652
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After surgery, temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle (1 cycle = 28 days).
Study: NCT00553267
Drug: fixed dose combination of telmisartan+amlodipine
Normalized name: amlodipine / telmisartan
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00553267
Drug: amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01310036
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 150 mg was administered orally daily until disease progression or unacceptable toxicity.
Study: NCT00003269
Drug: amifostine trihydrate
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003269
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003269
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00775749
Drug: transdermal nicotine patch
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The 7 mg transdermal nicotine patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
Study: NCT02722746
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural block infusion with Ropivacaine 0.2% will be provided as the anesthesia per standard of care during the procedure.
Study: NCT00736866
Drug: Acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
Study: NCT02997358
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 μg/m²/day s.c From day 3 to day 9
Study: NCT04580394
Drug: AD109
Normalized name: Adefovir dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral administration before bed
Study: NCT04580394
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration before bed
Study: NCT04580394
Drug: R-oxybutynin
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration before bed
Study: NCT02040883
Drug: Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
Study: NCT02040883
Drug: Tandospirone
Normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandospirone，30mg per day
Study: NCT00668200
Drug: Reclast (ZOL446, zoledronic acid)
Normalized name: Reclast
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mg i.v. annually (real-life, physician prescribed)
Study: NCT02646267
Drug: standard intensity warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: target international normalised ratio(INR) was 2.1-3.0
Study: NCT02646267
Drug: dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 110mg, twice a day, oral
Study: NCT01793519
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous
Study: NCT03101085
Drug: S-equol and Placebo
Normalized name: S-equol
DrugBank: Equol (DB11674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
Study: NCT03101085
Drug: Placebo and S-equol
Normalized name: S-equol
DrugBank: Equol (DB11674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
Study: NCT00067782
Drug: Atazanavir (immediate switch)
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, 400mg, Once daily, 48 weeks.
Study: NCT01793519
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infusion
Study: NCT01793519
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous
Study: NCT02494284
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6-month DAPT followed by clopidogrel monotherapy
Study: NCT02494284
Drug: Aspirin plus clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: standard long-term dual antiplatelet strategies (24-month DAPT followed by aspirin monotherapy)
Study: NCT00827034
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A: a single oral dose of warfarin 25 mg administered on Day 1 of the relevant dosing period, as tablets.
Study: NCT00827034
Drug: Dimebon
Normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
Study: NCT00827034
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
Study: NCT02108951
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 150mg hard gelatin capsules taken orally
Study: NCT02175173
Drug: Rufinamide
Normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administration of Inovelon 100mg or 200mg Tablets
Study: NCT00093769
Drug: bortezomib + rituximab
Normalized name: Bortezomib
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.~* Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients in either arm may crossover to the other arm if treatment is found to be ineffective.
Study: NCT01761747
Drug: ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03877718
Drug: Arm 3: Sumatriptan Succinate 100 mg capsule
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One capsule of sumatriptan succinate 100 mg
Study: NCT03877718
Drug: Arm 4: Promethazine HCl 18.75 mg
DrugBank: Promethazine (DB01069)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One capsule of promethazine HCl 18.75 mg
Study: NCT03877718
Drug: Arm 5: Promethazine HCl 37.5 mg
DrugBank: Promethazine (DB01069)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One capsule of promethazine HCl 37.5 mg
Study: NCT00421252
Drug: clopidogrel 600 mg
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel load \> 2hrs pre-angiography
Study: NCT01985126
Drug: Daratumumab 16 mg/kg (Part 1)
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion
Study: NCT01985126
Drug: Daratumumab 8 mg/kg (Part 1)
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion
Study: NCT01985126
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted
Study: NCT01985126
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.
Study: NCT01985126
Drug: Daratumumab (Part 2)
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.
Study: NCT03179839
Drug: sertraline, fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The participants can be adjustable once a week dose and the maximum dose does not exceed the maximum amount of instructions. And benzodiazepine drugs also can be used by the OCD patients with sleep disorders, but not be used continuously for more than two weeks. Besides this, other psychotropic drugs are not allowed to use. The use of drugs in this study are commonly used drugs with good safety, and its common adverse reactions include dry mouth, constipation, nausea, indigestion, dizziness, fatigue, sweating and so on.
Study: NCT06163755
Drug: Methylprednisolone 40 MG Injection
Normalized name: methylprednisolone 40 MG Injection
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-articular knee injection will be performed in patient with knee osteoarthritis who meets inclusion criteria. After Random assignment Patient will either get Intra-articular Morphine with Bupivacaine or Depomedrol with Bupivacaine.
Study: NCT03825380
Drug: Bimatoprost
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eyedrops